Inki Moon1, Eue-Keun Choi2, Jin-Hyung Jung3, Kyung-Do Han3, You-Jung Choi1, Jiesuck Park1, Jun Hwan Cho1, Euijae Lee1, Wonseok Choe1, So-Ryoung Lee4, Myung-Jin Cha1, Woo-Hyun Lim5, Seil Oh1. 1. Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea. 2. Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea. Electronic address: choiek17@snu.ac.kr. 3. Department of Biostatistics, College of Medicine, The Catholic University of, Seoul, Republic of Korea. 4. Department of Internal Medicine, Soon Chun Hyang University Hospital Seoul, Seoul, Republic of Korea. 5. Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Republic of Korea.
Abstract
BACKGROUND: Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease, associated with a number of cardiovascular diseases. We sought to investigate whether AS increases the risk of atrial fibrillation (AF) in a nationwide population-based study. METHODS: A total of 14,129 patients newly diagnosed with AS (mean age 41.8 ± 15.3 years, 72% male) were recruited from the Korean National Health Insurance Service database between 2010 and 2014 and followed up for new onset AF. Age- and sex-matched non-AS subjects (1:5, n = 70,645) were selected and compared with the AS patients. RESULTS: During a mean follow-up of 3.5 years, AF was newly diagnosed in 486 patients (114 patients of the AS group). The AS patients developed AF more frequently than the non-AS subjects (2.32 vs. 1.51 per 1000 person-years). In multivariate Cox regression analysis, AS was an independent risk factor for AF (Hazard ratio [HR] 1.28, 95% confidence interval [1.03-1.58]). The AS with tumor necrosis factor inhibitor (TNFi) therapy group showed higher risk for AF (HR 1.60 [1.02-2.39]). In younger patients of the AS group (patients <40 years old), the risk for AF was three times higher than patients at same age in the non-AS group. AS was an independent risk factor for AF in men, but not in women (HR 1.53 [1.18-1.95]; HR 1.42 [0.94-2.08], respectively). CONCLUSIONS: AS was an independent risk factor for AF, especially in those under 40 years of age and those administered TNFi. It would be reasonable to screen for AF and stroke prevention in these high-risk patients.
BACKGROUND:Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease, associated with a number of cardiovascular diseases. We sought to investigate whether AS increases the risk of atrial fibrillation (AF) in a nationwide population-based study. METHODS: A total of 14,129 patients newly diagnosed with AS (mean age 41.8 ± 15.3 years, 72% male) were recruited from the Korean National Health Insurance Service database between 2010 and 2014 and followed up for new onset AF. Age- and sex-matched non-AS subjects (1:5, n = 70,645) were selected and compared with the AS patients. RESULTS: During a mean follow-up of 3.5 years, AF was newly diagnosed in 486 patients (114 patients of the AS group). The AS patients developed AF more frequently than the non-AS subjects (2.32 vs. 1.51 per 1000 person-years). In multivariate Cox regression analysis, AS was an independent risk factor for AF (Hazard ratio [HR] 1.28, 95% confidence interval [1.03-1.58]). The AS with tumornecrosis factor inhibitor (TNFi) therapy group showed higher risk for AF (HR 1.60 [1.02-2.39]). In younger patients of the AS group (patients <40 years old), the risk for AF was three times higher than patients at same age in the non-AS group. AS was an independent risk factor for AF in men, but not in women (HR 1.53 [1.18-1.95]; HR 1.42 [0.94-2.08], respectively). CONCLUSIONS: AS was an independent risk factor for AF, especially in those under 40 years of age and those administered TNFi. It would be reasonable to screen for AF and stroke prevention in these high-risk patients.
Authors: Mahmood Mubasher; Tausif Syed; Amir Hanafi; Zhao Yu; Ibrahim Yusuf; Abdullah Sayied Abdullah; Mouhand Fh Mohamed; Richard Alweis; Mohan Rao; Ryan Hoefen; Mohammed I Danjuma Journal: Clin Med Insights Cardiol Date: 2020-10-28
Authors: Anna Södergren; Johan Askling; Karin Bengtsson; Helena Forsblad-d'Elia; Tomas Jernberg; Ulf Lindström; Lotta Ljung; Ängla Mantel; Lennart T H Jacobsson Journal: Clin Rheumatol Date: 2020-08-26 Impact factor: 2.980